Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21460097 | 0.92 | VNN1 (1.00) | VNN1BTD | |
| SCHEMBL21480277 | 0.91 | VNN1 (1.00) | VNN1BTD | |
| SCHEMBL21460184 | 0.88 | VNN1 (1.00) | VNN1BTD | |
| SCHEMBL21460074 | 0.88 | VNN1 (1.00) | VNN1BTD | |
| SCHEMBL26611801 | 0.87 | VNN1 (0.81) | VNN1BTD | |
| SCHEMBL21480231 | 0.86 | VNN1 (1.00) | VNN1BTD | |
| SCHEMBL26612302 | 0.85 | VNN1 (0.75) | VNN1BTD | |
| SCHEMBL19779278 | 0.84 | VNN1 (1.00) | VNN1BTD | |
| SCHEMBL19779441 | 0.84 | VNN1 (1.00) | VNN1BTD | |
| SCHEMBL19778553 | 0.83 | VNN1 (1.00) | VNN1BTD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2021-02-02 | — | — | US | claimed |
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-10-17 | — | — | US | claimed |
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | VNN1, DPYD, MVD | VNN1 1/4885BTD 105/4885 |
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | VNN1, DPYD, MVD | VNN1 1/4885BTD 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.